97 related articles for article (PubMed ID: 7593449)
1. Nitrendipine treatment in women with polycystic ovarian syndrome: evidence for a lack of effects of calcium channel blockers on insulin, androgens, and sex hormone-binding globulin.
Pasquali R; Cantobelli S; Vicennati V; Casimirri F; Spinucci G; de Iasio R; Mesini P; Boschi S; Nestler JE
J Clin Endocrinol Metab; 1995 Nov; 80(11):3346-50. PubMed ID: 7593449
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
3. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
4. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
Nestler JE; Jakubowicz DJ
J Clin Endocrinol Metab; 1997 Dec; 82(12):4075-9. PubMed ID: 9398716
[TBL] [Abstract][Full Text] [Related]
5. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
Apter D; Bützow T; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
[TBL] [Abstract][Full Text] [Related]
6. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome.
Ducluzeau PH; Cousin P; Malvoisin E; Bornet H; Vidal H; Laville M; Pugeat M
J Clin Endocrinol Metab; 2003 Aug; 88(8):3626-31. PubMed ID: 12915646
[TBL] [Abstract][Full Text] [Related]
7. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
8. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
[TBL] [Abstract][Full Text] [Related]
9. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
Wang A; Li M; Lu C
Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662
[TBL] [Abstract][Full Text] [Related]
10. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome.
Nestler JE; Barlascini CO; Matt DW; Steingold KA; Plymate SR; Clore JN; Blackard WG
J Clin Endocrinol Metab; 1989 Jun; 68(6):1027-32. PubMed ID: 2498378
[TBL] [Abstract][Full Text] [Related]
11. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
[TBL] [Abstract][Full Text] [Related]
12. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
Romualdi D; De Cicco S; Tagliaferri V; Proto C; Lanzone A; Guido M
J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
[TBL] [Abstract][Full Text] [Related]
13. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss.
Jakubowicz DJ; Nestler JE
J Clin Endocrinol Metab; 1997 Feb; 82(2):556-60. PubMed ID: 9024253
[TBL] [Abstract][Full Text] [Related]
14. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
[TBL] [Abstract][Full Text] [Related]
15. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Nestler JE; Powers LP; Matt DW; Steingold KA; Plymate SR; Rittmaster RS; Clore JN; Blackard WG
J Clin Endocrinol Metab; 1991 Jan; 72(1):83-9. PubMed ID: 1898744
[TBL] [Abstract][Full Text] [Related]
16. Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome.
Enli Y; Fenkci SM; Fenkci V; Oztekin O
Gynecol Endocrinol; 2013 Dec; 29(12):1036-9. PubMed ID: 23961784
[TBL] [Abstract][Full Text] [Related]
17. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
[TBL] [Abstract][Full Text] [Related]
18. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.
Cassar S; Teede HJ; Moran LJ; Joham AE; Harrison CL; Strauss BJ; Stepto NK
Clin Endocrinol (Oxf); 2014 Dec; 81(6):899-906. PubMed ID: 25040369
[TBL] [Abstract][Full Text] [Related]
19. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization.
Sir-Petermann T; Maliqueo M; Angel B; Lara HE; Pérez-Bravo F; Recabarren SE
Hum Reprod; 2002 Oct; 17(10):2573-9. PubMed ID: 12351531
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
Azziz R; Ehrmann D; Legro RS; Whitcomb RW; Hanley R; Fereshetian AG; O'Keefe M; Ghazzi MN;
J Clin Endocrinol Metab; 2001 Apr; 86(4):1626-32. PubMed ID: 11297595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
